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Abstract. Antimonial-containing drugs are the first line of treatment against Leishmaniasis. Resistance to antimo-
nials in Leishmania is proposed to be due to reduced uptake of trivalent antimony (SbIII) through the aquaglyceroporin
(AQP1). We investigated the uptake of SbIII and involvement of aquaglyceroporin in developing antimony resistance
phenotype in Leishmania donovani clinical isolates. SbIII accumulation, copy number of AQP1 gene, and transcript
levels were compared in antimony-sensitive versus -resistant isolates. Antimony-resistant field isolates showed reduced
uptake of SbIII. The copy number of AQP1 gene showed higher copy number in the antimony-resistant isolates when
compared with the sensitive isolates and did not correlate to the reduced uptake of SbIII. Downregulation of AQP1
RNA levels was not consistently found in the antimony-resistant isolates. Our studies indicate that while downregulation
of AQP1 may be one of the mechanisms of antimony resistance, it is however not an invariable feature.
INTRODUCTION
Visceral leishmaniasis (VL) is a protozoan parasitic disease
caused by Leishmania donovani and is often fatal if left un-
treated. Pentavalent antimonials such as sodium antimony
gluconate (SAG) are the standard first-line choice against the
disease.1 Although pentavalent antimonials are age-old con-
ventional therapy, the mechanism of action of SAG is not
precisely defined. General agreement is that pentavalent
form (SbV) is reduced to the more toxic trivalent form
(SbIII).2 Trivalent form of the antimony constitutes the active
form of drug against the parasite. The reduction of the metal
may take place either in the parasite3–6 or in the macro-
phages7 or in both. Resistance to SAG is increasing and has
been reported in several parts of the world.1,8 In the endemic
regions, resistance to this class of drugs is a major impediment
to treatment.8 It has been demonstrated that more than 60%
of the patients do not respond to SbV treatment in the Bihar
state of northern India.8–10 The mechanism of action and re-
sistance to SAG in the field isolates is less well defined. A
consistent resistance mechanism deduced from in vitro work
involves multiple steps and implicates trypanothione metabo-
lism and drug transport.11–14
The ABC transporter, MRPA, has been shown to confer
resistance to antimonials by sequestering metal-trypanothione
conjugates into an intracellular organelle.15 Our earlier work on
the clinical kala azar L. donovani isolates from India showed
MRPA overexpression as an important SAG resistance fac-
tor.16 Role of a metal-thiol efflux pump in antimony resis-
tance has also been reported but the nature of this pump is
not known.17 Yet another mechanism leading to downregu-
lation of an uptake system is the loss of an aquaglyceroporin
(AQP1) allele that has been reported to cause an increase in
resistance to SAG.18,19
Aquaglyceroporins (AQP1s) are the members of the aqua-
porin super family. They are membrane channels that permit
transport of small neutral solutes such as glycerol or urea.20
Glycerol Facilitator (GlpF) and Glycerol Channel Protein
(Fps1p), an aquaglyceroporin family member, have been re-
ported to transport SbIII in Escherichia coli21 and in Saccha-
romyces cerevisiae,22 respectively. In Leishmania species,
AQP1 has been shown to facilitate SbIII transport.18 In-
creased rates of uptake of SbIII correlated with the antimony
sensitivity of the wild-type and drug-resistant transfectants of
Leishmania18,19 suggesting AQP1 as the major route of entry
of trivalent antimony in laboratory conditions. In laboratory-
raised SbIII-resistant Leishmania strains, gene expression ex-
periments have shown that AQP1 transcript levels correlated
well with the accumulation of SbIII and resistance levels in
Leishmania.19
In the present study we examined the correlation between
the SAG sensitivity profiles of Indian field isolates of L. dono-
vani collected from SAG responsive and unresponsive patients
with SbIII accumulation. The status of AQP1 gene both at ge-
netic and transcriptional level and the correlation with SAG
resistance has been reported.
MATERIALS AND METHODS
Parasite and culture condition. Promastigotes of Leishma-
nia donovani strains AG83 (MHOM/IN/80/AG83), GE1
(MHOM/IN/80/GE1F8R) along with four untyped strains
2001, 41, NS2, and CK2 were isolated from patients with VL
and were routinely cultured at 22°C in modified M-199 me-
dium (Sigma, USA) supplemented with 100 U/mL penicillin
(Sigma, USA), 100 g/mL streptomycin (Sigma, USA), and
10% heat-inactivated fetal bovine serum (FBS; Gibco/BRL,
Life Technologies Scotland, UK). Clinical isolates obtained
from VL patients who responded to SAG chemotherapy were
designated as SAG-S (SAG-sensitive) whereas isolates from
VL patients who did not respond to SAG were designated as
SAG-R (SAG-resistant). Accordingly, SAG-S isolates used in
this study include AG83-S and 2001-S whereas the four
SAG-R isolates were 41-R, GE1-R, NS2-R, and CK2-R.
These isolates have been characterized earlier.16 The SAG-
resistant isolates were maintained in the absence of drug pres-
sure in vitro. The isolates have been passaged through ham-
sters or BALB/c mice to retain their virulence and impor-
tantly, their chemosensitivity profiles have remained
unchanged as measured periodically by amastigote-
macrophage infectivity assay reported earlier.16
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Chemosensitivity profiles of SAG-S and SAG-R promasti-
gotes to potassium antimony tartrate (SbIII). Briefly, (1 × 105
cells/200 L/well) log phase promastigotes of SAG-S and
SAG-R isolates were plated in triplicates in M199 medium
supplemented with 10% FBS in 96-well culture plate. After
24 h of incubation at 22°C, SbIII was added in increasing
concentrations (0–100 M). After 72 h of drug exposure, live
cells were counted using a hemocytometer. The 50% inhibi-
tory concentration (IC50) was extrapolated from the graph
representing different concentrations of SbIII plotted against
the percentage of viable cells.
Uptake assay. Uptake studies were done as described pre-
viously.19 Briefly, log phase Leishmania promastigotes were
washed twice with phosphate buffered saline (PBS, pH 7.4)
and were resuspended in PBS containing 10 mM glucose at a
density of 5 × 107 cells/mL. Cells were then incubated at 27°C
with 100 M SbIII for 30 minutes and an aliquot of 500 L
samples were collected at 0 and 30 minutes. After that cells
were pelleted down and washed twice with equal volume of
ice cold PBS, centrifuged at 17,000 × g for 1 minute at room
temperature, dried and digested with 0.05% of 70% nitric
acid for 2 h at 70°C, and then diluted with 3 mL of the high-
pressure liquid chromatography grade water. Antimony lev-
els were analyzed by Inductively Coupled Plasma Mass Spec-
troscopy (ICP-MS) as reported earlier.3,19 Each uptake assay
was repeated twice with duplicates in each set.
Cloning of full-length aquaglyceroporin (AQP1) gene from
antimony-sensitive and antimony-resistant L. donovani
strains. To clone the gene encoding aquaglyceroporin
(AQP1) from L. donovani-sensitive and -resistant strains,
PCR was performed using specific oligonucleotides, whose
sequence was based on Leishmania Genome Sequencing
Project of Leishmania infantum (www.ebi.ac.uk/parasites/
LGN/). DNA fragments of 945 bp were amplified from ge-
nomic DNA of 2001-S and GE1-R strains, using a sense
primer with a flanking XbaI site, 5-GC TCTAGA AT-
GAACTCTC CTACAAGCAC A-3, which coded for the
amino acid sequence MNSPTST at position 1-21, and the
antisense primer with a flanking HindIII site, 5-CCC
AAGCTT CTAGAAGTTGGGTGGAATGA-3, which cor-
responded to amino acid residues IIPPNF including the stop
codon, at position 926–945. Polymerase chain reaction (PCR)
was performed in a 50 L reaction volume containing 100 ng
of genomic DNA, 25 pmol each of gene-specific forward and
reverse primers, 200 M of each dNTP, 2 mM MgCl2, and 5
U Taq DNA polymerase (MBI Fermentas). The condition of
PCR was as follows: 94°C for 10 min, 94°C for 45 s, 60°C for
30 s, 72°C for 45 s, and 35 cycles. Final extension was carried
for 10 min at 72°C. Single band of 945-bp PCR products were
obtained and subcloned in to pGEM-T vector (Promega) and
subjected to automated sequencing. Sequence analysis was
performed by DNAstar whereas comparison with both se-
quences and with other sequences were performed using the
search algorithm BLAST. Multiple alignment of amino acid
sequences was performed using CLUSTAL W program.
Nucleic acid isolation and hybridization analysis. Genomic
DNA was isolated from ∼2 × 108 promastigotes (AG83–S,
2001–S, GE1–R, 41–R, CK2–R, and NS2–R) by standard pro-
cedure.23 Genomic DNA were digested with SalI or XhoI
restriction enzymes and subjected to electrophoresis in 0.8%
agarose gel. The fragments were transferred to HybondTM- N+
membrane (Amersham Pharmacia Biotech) and subjected to
Southern blot analysis.
Total RNA was isolated from ∼2 × 108 promastigotes
(AG83–S, 2001–S, GE1–R, 41–R, CK2–R, and NS2–R) using
TRI ReagentTM (Sigma). For Northern blot analysis, 15 g of
total RNA was fractionated by denaturing agarose gel elec-
trophoresis and transferred onto HybondTM- N+ membrane
following standard procedures.
Following the transfer of DNA and RNA onto nylon mem-
branes, the nucleic acids were cross-linked to the membrane
in UV cross linker. Prehybridization was done at 65°C for 4 h
in a buffer containing 0.5 M sodium phosphate; 7% SDS;
1 mM EDTA, pH 8.0, and 100 g/mL sheared denatured
salmon sperm DNA. The blots were hybridized with dena-
tured [´-32P] dCTP- labeled DNA probe at 106 cpm/mL,
which was labeled by random priming (NEB Blot kit, New
England Biolabs). The full length (945 bp) Leishmania dono-
vani aquaglyceroporin gene (AQP1) (genebank accession
number, EF600686) from the strain 2001-S was used as probe.
Membranes were washed, air dried, and exposed to imaging
plate. The image was developed by phosphor Imager (Fuji
film FLA-500, Japan) and RNA levels were quantified using
Image quant software.
RESULTS
Susceptibility of Leishmania isolates to potassium anti-
mony tartrate (SbIII). SAG sensitivity profiles of Leishmania
isolates (AG83–S, 2001–S, GE1–R, 41–R, CK2–R, and NS2–R)
has been reported earlier using amastigote-macrophage
model system and the IC50 values for AG83–S and 2001–S
were 9 ± 0.5 g/mL and 13 ± 1.5 g/mL, respectively while
that of the resistant field isolates GE1–R, 41–R, CK2–R, and
NS2–R were > 100 g/mL, 65 ± 3.4 g/mL, 55 ± 2.5 g/mL
and 24 ± 1.4 g/mL respectively to SAG.16 While the drug is
being used as pentavalent antimonial compound (SbV), the
active form of the drug is a trivalent antimony (SbIII).3 Pre-
vious studies have shown a correlation between resistance to
SbIII in both promastigotes and intracellular amastigotes.18,19
We therefore used promastigotes to check the effect of SbIII
on the parasites and have used promastigotes in the present
work for further characterization of SbIII transport. The IC50
value to SbIII of SAG-sensitive promastigotes, AG83–S and
2001–S were 15 ± 3.5 M and 8 ± 2.1 M respectively,
whereas the IC50 value of SAG-resistant field isolates GE1–
R, 41–R, CK2–R, and NS2–R were 23 ± 1.8 M, 25 ± 3.2 M,
22 ± 1.9 M, and 38 ± 2.2 M, respectively (Table 1). The
results indicated that 2001–S is most susceptible towards SbIII
when compared with the rest of the isolates. SAG-resistant
isolates had higher IC50 value with SbIII when compared with
the sensitive isolates AG83–S and 2001–S. The resistant iso-
TABLE 1
IC50 of promastigotes of SAG-sensitive and SAG-resistant L. dono-
vani field isolates to SbIII
Isolates Mean IC50 ± SD (M)
AG83-S 15 ± 3.5
2001-S 8 ± 2.1
GE1-R 23 ± 1.8
41-R 25 ± 3.2
CK2-R 22 ± 1.9
NS2-R 38 ± 2.2
IC50s were determined in promastigotes after 72 h of drug addition. The results are
mean ± SD of three independent experiments.
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lates GE1–R, NS2-R, 41–R, and CK2–R were ∼3–5-fold more
resistant to SbIII compared with the sensitive isolate.
Comparison of transport of potassium antimony tartrate
(SbIII) in SAG-R versus SAG-S field isolates. The effect of a
drug depends on the amount of drug transport and accumu-
lation inside the cells. The reduced uptake of the drug could
be a mechanism by which cells develop resistance to antimo-
nials.24 Lack of commercial source of 125Sb has made direct
measurement of Sb accumulation in Leishmania complex. In
the present study, we have used Inductively Coupled Plasma
Mass Spectroscopy (ICP-MS) to show SbIII accumulation in-
side the cells.3,19 We first compared the accumulation of SbIII
in a SAG-S and a SAG-R L. donovani as a function of time.
Accumulation of antimony in SAG-R isolate GE1-R showed
time-dependent decrease when compared with the accumu-
lation in SAG-S isolate, 2001-S (Figure 1A). We used 10 M
and 100 M concentrations of SbIII to compare the dose-
dependent accumulation of SbIII in a SAG-S isolate, 2001-S
and a SAG-R isolate, GE1-R. The accumulation of SbIII af-
ter 30 min was 7.0 ± 3.1 nmol/108 cells and 1.4 ± 0.3 nmol/108
cells in 2001-S and GE1-R respectively, when 10 M concen-
tration of SbIII was used. However, when 100 M concentra-
tion of SbIII was used the accumulation was 182 ± 11.0 nmol/
108 cells and 44.4 ± 3.9 nmol/108 cells in 2001-S and GE1-R
respectively (data not shown).
Efflux of SbIII from sensitive and resistant cells was com-
pared (Figure 1B). Both lines were loaded in the same fashion
(incubating with 100 M SbIII at 27°C for 30 min). After this
cells were washed and transferred to medium without SbIII
for 30 min. The resistant cell line, GE1-R, accumulated mark-
edly less SbIII over the loading period when compared with
the sensitive cells, 2001-S (51 ± 3.1 nmol per 108 cells com-
pared with 179.8 ± 9.8 nmol per 108 cells). The rate of efflux
over an initial phase (the first 5-min interval) occurred at a
similar rate in both cell lines (31 nmol per 108 cells in 2001-S,
over the first 5 min and 28 nmol per 108 cells in the resistant
line, GE1-R). Hereafter the rate of efflux tailed off quickly in
the resistant line approaching a plateau by 30 min of about
12.0 ± 0.6 nmol per 108 cells. In the sensitive line the rapid
rate of efflux continued for longer period than in the resistant
line although it also approached a plateau by the 30-min point
indicating about 72.4 ± 2.8 nmol per 108 cells retained in the
parasites (Figure 1B).
At zero time point SAG-sensitive and -resistant field iso-
lates showed < 10 nmol, SbIII accumulation within the cells.
It was found that the SAG-R isolates had reduced accumu-
lation of SbIII when compared with the SAG-S field isolates
(Figure 2). In comparison to 2001–S, SAG-R field isolates
GE1-R, 41-R, CK2-R, and NS2-R accumulated ∼4.5, 4.9, 3.3,
FIGURE 1. A, Time-dependent accumulation of SbIII in SAG-S
and SAG-R Leishmania donovani as measured by ICP-MS. Promas-
tigotes of 2001-S () and GE1-R () were incubated with 100 M
SbIII and samples were taken at different time points as described in
the Materials and Methods. Results are the mean ± SD of two rep-
licate experiments. B, Efflux of SbIII by SAG-S () and SAG-R ()
Leishmania donovani field isolates as measured by ICP-MS. Promas-
tigotes were incubated with 100 M SbIII at 27°C for 30 min, cen-
trifuged, washed three times with PBSG, and resuspended in drug-
free PBSG. Retained SbIII was measured between 0 and 30 min.
Results are mean ± SD of two replicate experiments.
FIGURE 2. Accumulation of SbIII in SAG-S and SAG-R Leish-
mania donovani field isolates as measured by ICP-MS. Promastigotes
were incubated with 100 M SbIII for 30 minutes at 27°C as de-
scribed in Materials and Methods. Data are shown as the mean ± SD
of two replicate experiments.
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and 6.8-fold less SbIII respectively (Figure 2). These transport
studies suggest that the SAG-R Leishmania isolates had re-
duced accumulation of SbIII when compared with the SAG-S
isolates.
Southern blot analysis of the aquaglyceroporin (AQP1)
gene in SAG-S and SAG-R field isolates. Southern blot analy-
sis clearly depicted that in L. donovani field isolates AQP1
gene showed variation in the gene copy number between
SAG-S and SAG-R isolates. Restriction enzyme SalI, which
cuts outside the gene producing 10.8 kb restriction fragment
(expected size) and XhoI, which cuts once inside the gene
producing 2.3 kb fragment (expected size) was used to check
the copy number of the gene. SalI digestion produced a single
hybridizing fragment of 10.8 kb that was observed in both
SAG-S isolate 2001-S and SAG-R isolates. However, SAG-R
strains, GE1–R and 41-R produced more than one low mo-
lecular weight hybridizing fragments in addition to 10.8 kb
band of expected size (Figure 3A), indicating that AQP1 exist
as a multiple copy gene in these two strains. Southern blot
analysis of XhoI digested genomic DNA showed that the
copy number of the AQP1 gene (expected band size of 2.3 kb)
in SAG-R isolates was higher than that of the SAG-S isolates
(Figure 3B).
Because the analysis of the Southern blot with AQP1 gene
probe in SAG-S and SAG-R field isolates showed genetic
polymorphism among the isolates we decided to clone the
AQP1 gene from a SAG-S isolate, 2001-S, and a SAG-R
isolate, GE1-R (which showed maximum resistance and ge-
netic polymorphism). The AQP1 gene from the two strains
was sequenced and the predicted protein was compared. The
predicted protein of the SAG-S isolate, 2001-S (genebank
accession number, EF600686) was similar to that of the SAG-R
isolate, GE1-R (genebank accession number, EU191226).
L. donovani AQP1 protein sequences obtained here showed
99%, 86%, and 82% homology to L. infantum (XP_001467265),
L. major (CAJ08141), and L. mexicana (AAW56828) respec-
tively (Figure 4).
Comparison of aquaglyceroporin gene expression in
SAG-S versus SAG-R field isolates. We studied the expres-
sion of the AQP1 gene by Northern blot analysis. In SAG-R
field isolates, 41-R, CK2–R, and NS2–R, the transcript levels
of AQP1 were found to be down regulated when compared
with the SAG-sensitive isolate, 2001-S (Figure 5). Densito-
metric scanning of AQP1 transcript level showed that SAG-
resistant field isolates, 41-R, CK2-R, and NS2-R showed
downregulation of transcript level by ∼1.7-, 3.7-, and 1.5-fold
respectively in comparison to the SAG-S isolate, 2001-S (Fig-
ure 5). Surprisingly, the strain GE1–R, which had been shown
earlier to be most resistant to SAG16 in comparison to all
other resistant isolates, had transcript levels that were com-
parable to that of the SAG-S isolate, 2001-S. Low transcript
levels of AQP1 were observed in AG83-S isolate when com-
pared with another SAG-S isolate, 2001-S.
DISCUSSION
Sodium antimony stibogluconate (SAG) is the drug of
choice against Leishmania and resistance to this drug is a
major problem in the field not only in the Indian subconti-
nent, but also throughout the world. This increase in resis-
tance to SAG has led to an upsurge in therapeutic failure, and
in the absence of limited chemotherapeutic alternatives, it is
extremely relevant that mechanisms of resistance be evalu-
ated in field isolates.
Decreased uptake of the drug is one of the mechanisms by
which resistance can occur. In case of Leishmania lesser ac-
cumulation of antimony could lead to resistance phenotype.24
It has been reported earlier that AQP1 is an important trans-
porter by which SbIII can accumulate within Leishmania cells
but may not be the only one.18,19,24 AQP1 modulates drug
sensitivity when expressed at increased levels in both promas-
tigotes and amstigotes.18 In Leishmania spp. transfection of
AQP1 restored SbIII transport and regained susceptibility to
antimony in resistant cells.18,19 It has been reported earlier
that reduced accumulation of SbIII in SbIII-resistant mutants
FIGURE 3. Southern blot analysis of the aquaglyceroporin gene in
SAG–S and SAG–R Leishmania donovani field isolates. Total geno-
mic DNA was isolated and digested with (A) SalI restriction enzyme,
which cuts external to the gene and (B) XhoI restriction enzyme,
which cuts once inside the gene. The digested DNA was electropho-
resed, blotted, and hybridized with an AQP1 specific probe of 945 bp.
The sizes of the hybridizing bands were determined using HindIII
digested -DNA. The blot was rehybridized with -tubulin probe to
monitor the amount of digested DNA layered on the gel. Lane 1:
AG83-S, Lane 2: 2001-S, Lane 3: GE1-R, Lane 4: 41-R, Lane 5:
CK2-R, Lane 6: NS2-R.
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could be due to decreased activity of SbIII channel, AQP1.18,19
Loss of AQP1 has been shown to produce resistance and in-
creased expression of AQP1 in drug-resistant parasites reversed
resistance.18
Our earlier studies using SAG-S and SAG-R clinical iso-
lates showed susceptibility to SAG as determined in vitro with
intracellular amastigotes correlated well with the clinical re-
sponse.16 The ABC transporter gene MRPA was amplified in
resistant field isolates as part of an extrachromosomal
circle.16 Amplification of MRPA was correlated to increase
RNA as determined by real-time PCR.16
In the present study, we looked at the involvement of aqua-
glyceroporin in developing SAG-resistance phenotype in
these L. donovani field isolates that have been characterized
earlier.16 To test this we monitored the uptake of SbIII by
SAG-S and SAG-R isolates. Reduced uptake of the drug in
SAG-R isolates was observed when compared with the up-
take in SAG-S isolates. Thus a correlation was observed be-
tween the levels of SbIII accumulation and sensitivity profiles
of the isolates. Uptake of SbIII in SAG-R field isolates cor-
related well with the earlier findings using the laboratory-
raised, antimony-resistant strains19 indicating a similar
mechanism could also be operative in the field isolates. The
decreased accumulation could be due to decreased uptake
possibly due to a point mutation in the putative channel or
increased efflux of the metal. The efflux results indicate that
the initial rate of efflux of SbIII in sensitive and resistant lines
is similar. There are two possible explanations of the ob-
served similar initial rates of efflux in the sensitive and resis-
tant lines. In the first case it is assumed that a protein involved
in efflux is found in similar levels in both lines and that the
available SbIII concentrations in both lines are high enough
to saturate the efflux capacity. In this situation, similar
amounts of efflux protein would result in similar rates of ef-
flux, despite the differing levels of intracellular antimony. Ac-
cording to this model, however, the fact that in the sensitive
FIGURE 4. Multiple sequence alignment of aquaglyceroporin protein sequences from Leishmania donovani; SAG-S strain, 2001-S
(ABQ84980) and SAG-R strain, GE1-R (EU191226), L. infantum (XP_001467265), L. major (CAJ08141), and L. mexicana (AAW56828) using
Bioedit Sequence Alignment editor online tool analysis program (http://www.mbio.ncsu.edu/BioEdit/bioedit.html). The amino acids are num-
bered to the right of the respective sequences. Residues that are conserved completely are marked with (∗) and residues conserved at least in three
sequences are marked with (:) below the respective sequences. L. donovani; 2001-S sensitive strain has 100% identity with L. donovani GE1-R
resistant strain, 99% identity with L. infantum, 86% identity with L. major, and 82% identity with L. mexicana.
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line the rate of efflux does diminish in time, and retained drug
remains ∼6-fold higher than those enabling rapid efflux from
the resistant cell line, would indicate that the sensitive line
was able to sequester more antimony than the resistant line
was able to sequester.
An alternative explanation could also account for similar
absolute rates of elimination in the initial phase. In this case,
because the resistant line has around 3-fold less internalized
drug at the start of the measured period, it could be that the
resistant line has a 3-fold higher level of efflux activity en-
abling it to excrete at a similar rate to the sensitive line. This
would assume that the quantity of substrate available for ef-
flux falls well beneath the saturating level of carrier for sub-
strate. To differentiate between these processes a more de-
tailed characterization of the kinetic parameters of the carrier
responsible for efflux would be required. Earlier observations
have reported no difference in the efflux of SbIII between the
sensitive and the resistant cells.24
We also monitored the copy number of AQP1 gene and the
RNA expression levels in SAG-S and SAG-R isolates. The
copy number of the AQP1 gene was higher in SAG-R isolates
in comparison to the SAG-S isolates (Figure 3B) and does not
correlate with the reduced SbIII uptake in SAG-R isolates
observed in the present study. This data differs from the ear-
lier findings using laboratory-raised mutants where the copy
number of AQP1 remained unchanged for all the resistant
mutants.19 Because Southern blot analysis of AQP1 gene
showed genetic polymorphism in the field isolates we cloned
AQP1 gene from one SAG-S isolate and one SAG-R isolate.
Our results indicate that at least in GE1-R, reduced accumu-
lation observed does not result from point mutation in the
coding sequence of AQP1 gene.
Previous studies have shown downregulation of AQP1
gene expression in SbIII-resistant mutants selected in the
laboratory and the levels of transcripts correlated with the
concentration of SbIII used for selecting the resistant mutants
and also with the reduced metal accumulation.19 Northern
blot analysis of the clinical isolates in the present study
showed downregulation in SAG-R isolates; 41-R, CK2-R, and
NS2-R when compared with 2001-S, a SAG-S strain. How-
ever, GE1-R, which had been reported earlier to be the most
resistant of all the isolates (IC50 > 100 g/mL)
16 showed
higher gene copy number and upregulation of AQP1 RNA
levels when compared with other resistant isolates and RNA
levels were more than that of the SAG-S isolate, 2001-S. In-
creased level of AQP1 transcript in GE1-R isolate and de-
creased RNA levels in AG83-S isolate indicates that besides
AQP1 other mechanisms of antimonial resistance are opera-
tive. Our studies indicate that while downregulation of AQP1
may be one of the mechanisms of antimony resistance it is
however not an invariable feature of such resistance. Though
our studies represent limited set of clinical isolates, however,
they do differ significantly from results obtained in selected
laboratory strains where AQP1 has been shown to be a key
determinant of antimony accumulation and susceptibility in
L. donovani.19 Similar exceptions were observed earlier in
amastigotes of L. infantum strain selected for resistance to
SbIII.19 It is also possible that an alternative pathway of SbIII
uptake different from AQP1 may exist in the field isolates.
Taken together this study suggested the role of AQP1 gene
in generation of antimony-resistant phenotype to be impor-
tant, but not a sole determinant of antimony resistance in the
Indian field isolates. Further studies with more number of
isolates are needed to address this question.
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